



FOR IMMEDIATE RELEASE

## Idorsia Implements Veeva Development Cloud in Less Than 12 Months

*Unified applications for clinical, regulatory, and quality help fast-growing start-up drive greater efficiency and compliance throughout development*

**BARCELONA, Spain —10 July, 2018 — Veeva Systems** (NYSE:VEEV) today announced that Idorsia Pharmaceuticals Ltd established an integrated development landscape with **Veeva Development Cloud**. With unified applications for clinical, regulatory, and quality on a single cloud platform, Idorsia now has the technology foundation to accelerate product innovation and support its global growth plans.

“With a strong pipeline of innovative new therapies, we needed cutting-edge cloud technology that could scale as we grow,” said Joseph Bejjani, CIO at Idorsia. “Our IT strategy had three guiding principles when it came to product selection – cloud-first, easy-to-use functionality, and integrated, platform-based solutions. Veeva met all three objectives within a very tight timeline.”

Idorsia is a fast-growing biopharmaceutical start-up focused on research and early-stage clinical development. Immediately after its founding, Idorsia set an aggressive timeline to transition to new clinical development systems within 12 months.

With Veeva Development Cloud, Idorsia has unified applications to streamline documents and workflows so teams have a single source of truth across clinical, regulatory, and quality. This eliminates manual, duplicative efforts and gives teams consistent information throughout development. Because Veeva Vault applications have the same modern and intuitive interface, teams work with greater speed and spend less time on training.

“Veeva gives us the right technology foundation to manage business processes, content, and data across the organization,” said Simone Mechler, associate director clinical & quality systems. “We exceeded our goal and went live within seven months. All regions and departments now have a consistent view of the products in development to drive greater operational efficiency and maintain compliance.”

Idorsia is using or plans to use multiple applications across Veeva Development Cloud suites, including **Vault eTMF** and **Vault CTMS** from **Vault Clinical Suite**; **Vault Registrations**, **Vault Submissions**, and **Vault Submissions Publishing** from **Vault RIM Suite**; and **Vault QMS** and **Vault QualityDocs** from **Vault Quality Suite**.

“Idorsia needed to bring together their applications for clinical, quality, and regulatory to streamline drug development,” said Rik Van Mol, vice president, R&D strategy, Europe at Veeva. “Veeva Development Cloud helps life sciences companies like Idorsia achieve alignment across headquarters, sites, and countries and increase communication, collaboration, and compliance across the functions.”

### Additional Information

For more about Veeva Development Cloud, visit: [veeva.com/eu/VeevaDevelopmentCloud](https://veeva.com/eu/VeevaDevelopmentCloud)

Connect with Veeva on LinkedIn: [linkedin.com/company/veeva-systems](https://linkedin.com/company/veeva-systems)

Follow @veevasystems on Twitter: [twitter.com/veeva\\_eu](https://twitter.com/veeva_eu)

Like Veeva on Facebook: [facebook.com/veevasystems](https://facebook.com/veevasystems)

### About Veeva Systems

Veeva Systems Inc. is a leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva has more than 625 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. Veeva

is headquartered in the San Francisco Bay Area, with offices in Europe, Asia, and Latin America. For more information, visit [veeva.com](http://veeva.com).

### **Forward-looking Statements**

This release contains forward-looking statements, including the market demand for and acceptance of Veeva's products and services, the results from use of Veeva's products and services, and general business conditions, particularly in the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva's historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva's expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva's financial results are included under the captions, "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations," in the company's filing on Form 10-Q for the period ended April 30, 2018. This is available on the company's website at [veeva.com](http://veeva.com) under the Investors section and on the SEC's website at [sec.gov](http://sec.gov). Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.

###

### **Contact:**

Sue Glanville / Cate Bonthuys Veeva Systems Inc.  
[sue@catalystcomms.co.uk](mailto:sue@catalystcomms.co.uk) / [cate@catalystcomms.co.uk](mailto:cate@catalystcomms.co.uk)  
+44 (0) 7715 817589 / +44 (0) 7746 546773